Search Follow us

imugene

1 - 8 of 8
Sort by: popularity | newest
Page  of 1
Imugene

Checkpoint inhibitor vaccine programme accelerated

Outlook | Pharmaceutical & healthcare | 16 Aug 2018

Imugene has in-licenced a pipeline of B-cell vaccines that complements and advances its in-house programme. The deal has brought forward significant value-creation opportunities while maintaining Imugene's focus on B-cell vaccine technologies. It accelerates the key PD-1 and PD-1/HER2 combo programmes by two years compared to its original pipeline. The company is well funded to accelerate key clinical studies for the newly combined pipeline. Our valuation is A$147m or 4.1 cents per share.

Imugene

Executive interview - Imugene

Edison TV: | Pharmaceutical & healthcare | 09 Mar 2017

Imugene is a clinical-stage immuno-oncology company. Its lead product is HER-Vaxx, a B-cell peptide vaccine for the treatment of gastric cancer. HER-Vaxx is an immuno-oncology therapy designed to treat tumours that overexpress the HER-2/neu receptor, such as breast cancer and gastric cancer. HER-Vaxx has successfully completed a Phase I study in breast cancer and has commenced a Phase Ib/II study in gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets. Imugene has broadened its pipeline with the acquisition of arginine modulators (small molecules) to develop to preclinical proof of concept.

Imugene

Termination of coverage

Update | Pharmaceutical & healthcare | 21 Sep 2016

Edison Investment Research is terminating coverage on Imugene (IMU). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Imugene

Anti-tumour vaccine trial to start mid-2016

Outlook | Pharmaceutical & healthcare | 21 Feb 2016

Imugene will test its reformulated therapeutic cancer vaccine, HER-Vaxx, in gastric cancer at trial sites in Asia. The Phase Ib/II trial is expected to start in mid-2016. HER-Vaxx aims to replicate or improve on the combination of two proven therapeutic antibodies, Herceptin and Perjeta (Roche). Imugene aims to gain a major pharma deal following Phase II data in the buoyant cancer immunotherapy area. A$3.0m raised in October gives it sufficient funds to undertake the Phase Ib component of the trial.

Imugene

HER-Vaxx antibodies outperform Herceptin

Update | Pharmaceutical & healthcare | 09 Jul 2015

Imugene has developed a more potent formulation of its therapeutic cancer vaccine, HER-Vaxx, which will be tested in a Phase Ib/II trial in gastric (stomach) cancer in H215. HER-Vaxx could replicate or improve on the combination of two proven therapeutic antibodies, Herceptin and Perjeta (Roche), which significantly improves survival in breast cancer and may do so in gastric cancer. Imugene aims to gain a major pharma deal following Phase II data in the buoyant cancer immunotherapy area.

Imugene

On track for anti-tumour vaccine trial in H215

Update | Pharmaceutical & healthcare | 13 Apr 2015

Imugene is on track to initiate a Phase Ib/II trial of its gastric (stomach) cancer therapeutic vaccine, HER-Vaxx, in H215. HER-Vaxx aims to replicate and improve on the combination of two proven therapeutic antibodies, Herceptin and Perjeta (Roche), which significantly improves survival in breast cancer and may do so in gastric cancer. Global gastric cancer incidence is 934,000 cases with few current therapeutic options and low survival. Imugene raised A$3.6m in H214, which gives it sufficient funds to initiate the Phase Ib/II trial, with the aim of gaining a major pharma deal following Phase II data in the buoyant cancer immunotherapy area.

Imugene

Potent anti-tumour vaccine effect

Initiation | Pharmaceutical & healthcare | 26 Nov 2014

Imugene is progressing its gastric (stomach) cancer therapeutic vaccine, HER-Vaxx, into a Phase Ib/II. This aims to replicate and improve on the combination of two proven therapeutic antibodies, Herceptin and Perjeta (Roche), which significantly improves survival in breast cancer and may do so in gastric cancer. Global gastric cancer incidence is 934,000 cases with few current therapeutic options and low survival. In the HER-Vaxx Phase I, management observes that patient antibodies displayed potent anti-tumour activity with an immune response. Imugene has placed A$2.25m of shares and announced a share purchase plan to initiate Phase Ib/II, with the aim of progressing the study to gain a major pharma deal following Phase II data in the buoyant cancer immunotherapy area.

Imugene

Progressing HER-Vaxx into a gastric Phase II

QuickView | Pharmaceutical & healthcare | 15 Sep 2014

Imugene is developing a Phase II in second-line cancer for its acquired HER-Vaxx therapeutic vaccine targeting HER2+ gastric cancer patients. HER-Vaxx may replicate the antibody combination of Herceptin and Perjeta (Roche) that shows impressive survival efficacy in breast cancer. Gastric cancer is seen as a more promising large, poorly-served market. Phase I (in breast cancer) showed safety with the virosome-based vaccine stimulating good antibody responses in eight of 10 patients. The Phase II trial will take two years to run and cost A$3-5m with the aim of gaining a major deal from 2017.